The DNA damage response (DDR) is a critical cellular defense mechanism that becomes compromised in neurodegenerative diseases. In 4R-tauopathies, tau pathology coincides with elevated DNA damage in neurons and glia, contributing to cellular senescence and progressive neuronal loss. Neurons are particularly vulnerable to DNA damage due to their high metabolic activity, oxidative phosphorylation, and post-mitotic state that limits DNA damage tolerance mechanisms.
Multiple 4R-tauopathies show evidence of:
- Accumulation of DNA double-strand breaks (DSBs)
- Impaired base excision repair (BER)
- Reduced nucleotide excision repair (NER) capacity
- Chronic activation of DNA damage response pathways including p53, ATM, and ATR
Tau protein can directly interact with DNA and chromatin remodeling complexes. In 4R-tauopathies:
- Tau mislocalizes to the nucleus in affected neurons
- Nuclear tau disrupts DNA repair machinery recruitment
- Tau pathology correlates with γH2AX foci (DNA damage markers)
The tumor suppressor p53 is a central regulator of DNA damage responses:
- PSP, CBD, and AGD show p53 accumulation in affected neurons
- p53-mediated apoptosis is elevated, contributing to neuronal loss
- p53 polymorphisms may modify disease severity
BER is the primary pathway for repairing oxidative DNA damage:
- 8-oxoguanine (8-oxoG) accumulation is documented in PSP and CBD brains
- OGG1 (8-oxoguanine DNA glycosylase) activity is reduced
- PARP1 overactivation leads to NAD+ depletion and energy crisis
- Severe DNA damage in the subthalamic nucleus, globus pallidus, and brainstem
- Enhanced PARP1 activation in tau-containing neurons
- Compromised repair in dopaminergic neurons of the substantia nigra
- DNA damage in motor cortex and basal ganglia
- TDP-43 co-pathology may compound DNA repair deficits
- Upregulated ATM/ATR signaling in affected regions
- Prominent DNA damage in the limbic system
- 4R-tau pathology associated with DNA repair protein sequestration
- Cognitive decline correlates with DNA damage markers
- White matter oligodendrocyte vulnerability to DNA damage
- Myelin breakdown associated with impaired repair
- Astrocytic DNA damage response activation
- Some MAPT mutations directly affect DNA repair gene regulation
- Earlier onset of DNA damage compared to sporadic 4R-tauopathies
- Genotype-specific DNA repair phenotypes
- PARP inhibitors (e.g., olaparib) reduce PARP-mediated cell death
- NAD+ precursors restore PARP1 function and energy balance
- p53 modulators may reduce apoptotic neuronal loss
- CoQ10 and mitochondrial antioxidants reduce secondary DNA damage
- Dietary interventions targeting oxidative stress
- NRF2 activators enhance endogenous antioxidant responses
- Eliminating DNA damage-induced senescent cells
- Reducing SASP-associated neuroinflammation
Tau protein undergoes pathological phosphorylation, truncation, and aggregation in 4R-tauopathies, leading to:
- Nucleocytoplasmic translocation: Hyperphosphorylated tau can enter the nucleus
- DNA binding: Tau has been shown to directly bind DNA, particularly in AT-rich regions
- Chromatin remodeling disruption: Tau interacts with histone deacetylases (HDAC6) and other chromatin regulators
- Transcription factor sequestration: Nuclear tau may sequester transcription factors involved in DNA repair
Mitochondrial dysfunction in tauopathies leads to:
- Increased ROS production: Complex I dysfunction increases superoxide production
- 8-oxoguanine accumulation: Oxidative DNA damage accumulates in affected brain regions
- Mitochondrial DNA vulnerability: mtDNA is particularly vulnerable due to proximity to ROS sources
- NRF2 pathway dysfunction: Antioxidant response element pathway is impaired in 4R-tauopathies
BER is the primary pathway for repairing oxidative DNA damage:
- PARP1 overactivation: Chronic DNA damage leads to PARP1 overactivation, depleting NAD+ and ATP
- OGG1 dysfunction: 8-oxoguanine glycosylase activity is reduced in PSP and CBD
- APE1 endonuclease: Activity is compromised
- DNA polymerase β: Limited in neurons, is a rate-limiting step
NER repairs bulky DNA adducts:
- XPC and CSA/CSB dysfunction: Cockayne syndrome proteins are affected
- Transcription-coupled NER (TC-NER): Particularly vulnerable in post-mitotic neurons
- Global genome NER (GG-NER): Reduced capacity in affected regions
MMR fidelity declines with aging:
- MSH2/MSH6 complex: Altered expression in tauopathy brains
- MLH1/PMS2: Reduced in certain brain regions
¶ Homologous Recombination (HR) and Non-Homologous End Joining (NHEJ)
DNA double-strand break repair:
- HR deficiency: Limited in post-mitotic neurons due to cell cycle arrest
- Classical NHEJ (c-NHEJ): Predominant pathway but error-prone
- Alternative NHEJ (alt-NHEJ): Compensatory pathway, more error-prone
- 53BP1 recruitment: Altered in tauopathy neurons
The p53 tumor suppressor is central to DNA damage-induced cell death:
- p53 accumulation: Elevated p53 levels in affected neurons
- Transcriptional activation: p53 activates pro-apoptotic genes (BAX, PUMA, NOXA)
- Mitochondrial localization: p53 translocates to mitochondria, causing permeabilization
- p53 polymorphisms: TP53 codon 72 polymorphism may influence disease severity
PARP1-mediated cell death (parthanatos) is prominent:
- NAD+ depletion: Overactivation depletes cellular NAD+
- ATP depletion: Energy failure leads to cell death
- AIF translocation: Apoptosis-inducing factor translocates to nucleus
- DNA fragmentation: Massive DNA fragmentation occurs
¶ Neuroinflammation and DNA damage
Astrocytes and microglia also show DNA damage:
- Reactive astrogliosis: DNA damage markers elevated in astrocytes
- Microglial activation: Chronic activation leads to DNA damage
- SASP release: Senescent glia release inflammatory cytokines
- NLRP3 inflammasome: Activation by DNA damage
Damaged neurons may expose DNA:
- Anti-NMDA receptor antibodies: Found in some PSP patients
- DNA-containing extracellular vesicles: May trigger inflammatory responses
- cGAS-STING activation: Cytosolic DNA sensing pathway
Cerebrospinal fluid biomarkers:
- 8-oxoguanine: Elevated in CSF of PSP patients
- PAR poly(ADP-ribose): Marker of PARP1 activation
- Aβ and tau: May correlate with DNA damage burden
MRI findings:
- Subthalamic nucleus: Shows prominent DNA damage in PSP
- Brainstem regions: Vulnerable to oxidative damage
- White matter hyperintensities: Correlate with DNA damage burden
Pharmacological approaches:
- Olaparib (AZD2281): FDA-approved PARP inhibitor, in trials for neurodegeneration
- Rucaparib: Another PARP1/2 inhibitor under investigation
- NAD+ boosters: Nicotinamide riboside, NMN may support DNA repair
Clearance of senescent cells:
- Dasatinib + Quercetin: Combined senolytic approach
- ABT-263 (Navitoclax): Bcl-2 inhibitor with senolytic activity
- Fisetin: Natural senolytic flavonoid
Endogenous antioxidant enhancement:
- CoQ10: Supports mitochondrial electron transport
- MitoQ: Mitochondria-targeted antioxidant
- NRF2 activators: Sulforaphane, bardoxolone methyl
- Jellinger et al., DNA damage in progressive supranuclear palsy (2001)
- Fischer et al., p53 in neurodegenerative disease (2015)
- Scheffler et al., PARP and DNA repair in neurodegeneration (2015)
- Matsuzaki et al., Tau and DNA damage response (2015)
- Khader et al., OGG1 and 8-oxoguanine in PSP (2019)
- Coppola-Selvam et al., Nucleotide excision repair in neurodegeneration (2020)
- Itoh et al., Mitochondrial DNA damage in PSP (2008)
- Song et al., cGAS-STING in tauopathy (2021)
- D'Erchia et al., PARP1 and parthanatos in neurodegeneration (2022)
- Fraser et al., DNA damage response in aging brain (2019)
- Wang et al., Senolytic strategies in tauopathy (2021)
- Ito et al., NRF2 and antioxidant response in PSP (2020)
- Yuan et al., DNA damage in astrocytes (2018)
- Zhang et al., p53 polymorphisms in PSP (2017)
- Hofmans et al., Biomarkers of DNA damage in CSF (2023)
- Zheng et al., MitoQ and neuroprotection (2022)
- Kahl et al., CoQ10 supplementation in PSP (2008)
- Wellington et al., Sulforaphane in neurodegeneration (2019)
- Castello et al., DNA damage imaging in PSP (2017)
- Rossi et al., Chromatin remodeling in tauopathy (2022)